Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference

ATLANTA, March 25, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company will participate in a panel at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest, being held March 28th – 30th from 9:00 am – 5:30 pm ET.

During this on-demand virtual conference, Kathy Lee-Sepsick, Founder, President and Chief Executive Officer, will participate in the panel detailed below:

Panel title: “Advances in Women's Health: From Clinical to Commercial.”
Panel Description: From the bench to commercial, advances in the women’s health category are expanding available options and unlocking opportunities.
Panel day/ time: Monday, March 28^th from 3:00 pm – 4:30 pm ET

To register and listen to the panel discussion, sign up here.

About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc permanent birth control and FemaSeed localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue, is currently marketed in the United States. Femasys is also advancing FemCerv, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
[phone]
[e-mail]

Media
Sky Striar
LifeSci Communications
[e-mail]

Femasys Inc.
Investor Contact:
[e-mail]

Media Contact:
[e-mail]